What is uremia? Retention versus oxidation

Blood Purification

Volumn 24, Issue 1, 2006, Pages 33-38

  Vanholder, R ^a   Schepers, E ^a   Meert, N ^a   Lameire, N ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Guanidino compounds; Retention solutes; Uremic toxins

Indexed keywords

DINUCLEOSIDE PHOSPHATE; GUANIDINE DERIVATIVE; INDOLE DERIVATIVE; PEPTIDE; PHENOL DERIVATIVE; PHENYLACETIC ACID; POLYPHOSPHATE; UREMIC TOXIN;

DIALYSIS; HUMAN; INFLAMMATION; KIDNEY CLEARANCE; OXIDATION; PRIORITY JOURNAL; REVIEW; SOLUTE; UREMIA; URINE RETENTION;

HEMODIALYSIS SOLUTIONS; HUMANS; INFLAMMATION; OXIDATION-REDUCTION; RENAL DIALYSIS; UREMIA;

EID: 29244440718     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089434     Document Type: Review

References (32)

1. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
2. Ward RA, Brinkley KA: A proteomic analysis of proteins removed by ultrafiltration during extracorporeal renal replacement therapy. Contrib Nephrol 2004;141:280-291.
3. Ward RA, Ouseph R, McLeish KR: Effects of high-flux hemodialysis on oxidant stress. Kidney Int 2003;63:353-359.
4. Sarnatskaya VV, Ivanov AI, Nikolaev VG, Rotellar E, von Appen K, Haspar M, Maslenny VN, Klinkmann H: Structure and binding properties of serum albumin in uremic patients at different periods of hemodialysis. Artif Organs 1998;22:107-115.
5. Jankowski J, Hagemann J, Yoon MS, van der Giet M, Stephan N, Zidek W, Schluter H, Tepel M: Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 2001;59:1134-1141.
6. Jankowski V, Vanholder R, Henning L, Karadogan S, Zidek W, Schluter H, Jankowski J: Isolation and quantification of dinucleoside polyphosphates by using monolithic reversed phase chromatography columns. J Chromatogr 2005;819:131-139.
7. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J: Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. Nat Med 2005;11:223-227.
8. De Deyn PP, D'Hooge R, Van Bogaert PP, Marescau B: Endogenous guanidino compounds as uremic neurotoxins. Kidney Int 2001;59(suppl 78):S77-S83.
9. De Deyn PP, Marescau B, Cuykens JJ, Van Gorp L, Lowenthal A, De Potter WP: Guanidino compounds in serum and cerebrospinal fluid of non-dialyzed patients with renal insufficiency. Clin Chim Acta 1987;167:81-88.
10. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-496.
11. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
12. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billiouw JM, Lornoy W, De Deyn PP: Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997;46:1024-1031.
13. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004;65:2184-2192.
14. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-126.
15. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, De Santo NG: Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004;15:2747-2754.
16. Eloot S, Torremans A, De Smet R, Marescau B. De Wachter D, De Deyn PP, Lameire N, Verdonck P, Vanholder R: Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int 2005;67:1566-1575.
17. Vanholder RC, De Smet RV, Ringoir SM: Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992;38:1429-1436.
18. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R: Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50-57.
19. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004;65:442-451.
20. 2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 2003;63:1764-1775.
21. Canalejo A, Almaden Y, De Smet R, Glorieux G, Garfia B, Luque F, Vanholder R, Rodriguez M: Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. Kidney Int 2003;63:732-737.
22. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003;64:2238-2243.
23. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, Vanholder R: Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003;49:470-478.
24. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D'Esposito M, D'Urso M, Galletti P, Zappia V: Folate treatment and unbalanced methyla tion and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693-1699.
25. De Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K: Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005;51:1535-1538.
26. 2+ ATPase in end-stage renal failure. J Am Soc Nephrol 1998;9:1249-1257.
27. Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M: Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003;112:256-264.
28. Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC: Proteomics: a novel tool to unravel the pathophysiology of uraemia. Nephrol Dial Transplant 2004;19:3068-3077.
29. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-2532.
30. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695-725.
31. Glorieux G, Vanholder R, Lameire N: Advanced glycation and the immune system: stimulation, inhibition or both? Eur J Clin Invest 2001;31:1015-1018.
32. Bernheim J, Rashid G, Gavrieli R, Korzets Z, Wolach B: In vitro effect of advanced glycation end-products on human polymorphonuclear superoxide production. Eur J Clin Invest 2001;31:1064-1069.